{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134769","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.331253+00:00","generated_at":"2026-06-02T06:07:58.725047+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Wave Life Sciences Q1 net loss $31.6M; cash $180.9M; pipeline milestones on track","bullets":["Q1 revenue $12.5M (vs $12.9M YoY); net loss $31.6M (vs $27.4M). Cash $180.9M; plus $12M from GSK milestone in April.","RestorAATion-2 for AATD underway; proof-of-mechanism data expected in 2024.","INHBE obesity program targets 1Q 2025 trial start; preclinical weight loss similar to semaglutide with fat loss, no muscle loss.","FORWARD-53 DMD 24-week dystrophin data expected 3Q 2024; SELECT-HD multi-dose data expected 2Q 2024.","Appointed Dr. Erik Ingelsson as CSO to drive genetic target discovery; GSK advanced two programs triggering $12M payment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134769","json":"https://secwatch.observer/filing/0001193125-24-134769.json","markdown":"https://secwatch.observer/filing/0001193125-24-134769.md","text":"https://secwatch.observer/filing/0001193125-24-134769.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524134769/0001193125-24-134769-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524134769/d813742d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:07:58.725047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4377d486015ac3bf4d8ba36987119cae36e45e47","claim":"Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312524134769/0001193125-24-134769-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}